In our study, MMR status appeared to act as an independent prognostic biomarker for DFS in patients with stage III colon cancer that had received adjuvant FOLFOX chemotherapy a result that is consistent with other recent studies[6,23]. This evidence concerns the gene MRC1 and malignant colon neoplasm.